Immunicum: Combination Trial with Keytruda Proceeds
Redeye views the safety update from the Phase Ib ILIAD trial as encouraging, allowing for a continuation of investigations into a combination with checkpoint inhibitors. We reiterate our base case of SEK 15. 4.